These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1543 related items for PubMed ID: 11850229

  • 1. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A, Howell SJ, Clarke R, Anderson E.
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [Abstract] [Full Text] [Related]

  • 2. Future use of selective estrogen receptor modulators and aromatase inhibitors.
    Howell A.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
    [Abstract] [Full Text] [Related]

  • 3. Are aromatase inhibitors superior to antiestrogens?
    Howell A, Buzdar A.
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [Abstract] [Full Text] [Related]

  • 4. Selective oestrogen receptor modulators, aromatase inhibitors and the female breast.
    Howell A.
    Curr Opin Obstet Gynecol; 2005 Aug; 17(4):429-34. PubMed ID: 15976552
    [Abstract] [Full Text] [Related]

  • 5. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 6. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ, Johnston SR, Howell A.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [Abstract] [Full Text] [Related]

  • 7. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ, Dawson C, Lawrence DH, Bliss JM.
    Cochrane Database Syst Rev; 2007 Jan 24; (1):CD003370. PubMed ID: 17253488
    [Abstract] [Full Text] [Related]

  • 8. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE.
    Am J Clin Oncol; 2003 Aug 24; 26(4):S27-33. PubMed ID: 12902874
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F, GIM Investigators.
    Lancet Oncol; 2018 Apr 24; 19(4):474-485. PubMed ID: 29482983
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy.
    Ragaz J.
    J Steroid Biochem Mol Biol; 2001 Dec 24; 79(1-5):133-41. PubMed ID: 11850217
    [Abstract] [Full Text] [Related]

  • 11. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC, Brodie AM.
    Steroids; 2007 Jan 24; 72(1):7-25. PubMed ID: 17169390
    [Abstract] [Full Text] [Related]

  • 12. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS.
    Ann Oncol; 2008 Jan 24; 19(1):16-27. PubMed ID: 17693420
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor effects of letrozole.
    Miller WR, Anderson TJ, Dixon JM.
    Cancer Invest; 2002 Jan 24; 20 Suppl 2():15-21. PubMed ID: 12442345
    [Abstract] [Full Text] [Related]

  • 14. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 24; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 15. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S, Sharma R, Hamilton A, Beith J.
    Cochrane Database Syst Rev; 2009 Oct 07; 2009(4):CD004562. PubMed ID: 19821328
    [Abstract] [Full Text] [Related]

  • 16. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE.
    Clin Cancer Res; 2001 Dec 07; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [Abstract] [Full Text] [Related]

  • 17. Challenges in the endocrine management of breast cancer.
    Mouridsen HT, Rose C, Brodie AH, Smith IE.
    Breast; 2003 Aug 07; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [Abstract] [Full Text] [Related]

  • 18. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C.
    Am J Clin Oncol; 2003 Aug 07; 26(4):S9-16. PubMed ID: 12902872
    [Abstract] [Full Text] [Related]

  • 19. The endocrine prevention of breast cancer.
    Howell A.
    Best Pract Res Clin Endocrinol Metab; 2008 Aug 07; 22(4):615-23. PubMed ID: 18971122
    [Abstract] [Full Text] [Related]

  • 20. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ, Harvey HA.
    Endocr Relat Cancer; 1999 Mar 07; 6(1):75-92. PubMed ID: 10732791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.